Luminescent in vivo glucose measurement

• US 6,383,767 B1
• Filed: 01/21/2000
• Issued: 05/07/2002
• Est. Priority Date: 01/21/2000
• Status: Expired due to Term

• Current Assignee: Cilag Gmbh International (Johnson & Johnson)
• Original Assignee: Motorola, Inc. (Motorola Solutions, Inc.)
• Inventors: Polak, Anthony J.
• Primary Examiner(s): GITOMER, RALPH J
• Application Number:
  US09/489,372
• Time in Patent Office: 837 Days
• Field of Search: 435/14, 422/82.06, 424/9.1, 424/9.8, 424/425, 436/172, 600/342
• US Class Current: 435/14
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/1459 invasive, e.g. introduced into the body by a catheter A61B5/1464 takes precedence
• CPC Class Codes: A61K 49/0013 Luminescence
• CPC Class Codes: A61K 49/0017 Fluorescence in vivo
• CPC Class Codes: A61K 49/0054 Macromolecular compounds, i.e. oligomers, polymers, dendrimers
• CPC Class Codes: A61K 49/0067 quantum dots, fluorescent nanocrystals
• CPC Class Codes: B82Y 10/00 Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
• CPC Class Codes: B82Y 20/00 Nanooptics, e.g. quantum optics or photonic crystals
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

A luminescent in vivo glucose measurement method and apparatus is provided. The luminescent in vivo glucose measurement method includes the steps of illuminating displaced luminescent molecules with illuminating light, the displaced luminescent molecules and associated captive glucose analogue molecules being contained within an implanted luminescent in vivo measurement apparatus implanted within the interstitial fluid of the subject, and measuring an emitted light, the emitted light being emitted in response to the illumination, wherein the emitted light is related to the glucose level in the interstitial fluid.

Claims

1. A luminescent in vivo glucose measurement method for measuring a glucose level in an interstitial fluid of a subject, comprising the steps of:

displacing luminescent molecules and associated captive glucose analogue molecules into an illumination region;

illuminating said displaced luminescent molecules within said illumination region with illuminating light, said displaced luminescent molecules and associated captive glucose analogue molecules being contained within an implanted luminescent in vivo measurement apparatus implanted within said interstitial fluid of said subject; and

measuring an emitted light, said emitted light being emitted in response to said illumination;

wherein said emitted light is related to said glucose level in said interstitial fluid.

2. The luminescent in vivo glucose measurement method of claim 1, wherein said glucose level in said interstitial fluid is substantially equal to a blood glucose level.

3. The luminescent in vivo glucose measurement method of claim 1, wherein said method is used to measure a glucose level in a bloodstream of said subject.

4. The luminescent in vivo glucose measurement method of claim 1, wherein said displaced luminescent molecules are inorganic.

5. The luminescent in vivo glucose measurement method of claim 1, wherein said emitted light is correlated to a interstitial glucose level.

6. The luminescent in vivo glucose measurement method of claim 1, wherein said luminescent in vivo measurement apparatus is implanted about three to about four millimeters below an outer surface of a patient'"'"'s skin.

7. The luminescent in vivo glucose measurement method of claim 1, wherein said illuminating light is of a first wavelength and said emitted light is of a second wavelength.

8. The luminescent in vivo glucose measurement method of claim 1, wherein said illuminating light is an infrared light.

9. The luminescent in vivo glucose measurement method of claim 1, wherein a wavelength of said illuminating light is in a range of about 800 nanometers to about 2000 nanometers.

10. The luminescent in vivo glucose measurement method of claim 1, wherein a wavelength of said illuminating light is about 830 nanometers and a wavelength of said emitted light is about 900 nanometers.

11. The luminescent in vivo glucose measurement method of claim 1, wherein said illuminating light travels from outside said subject, through said subject'"'"'s skin, and into said luminescent in vivo measurement apparatus.

12. The luminescent in vivo glucose measurement method of claim 1, wherein said emitted light travels from said luminescent in vivo measurement apparatus, through said subject'"'"'s skin, and to a region outside said subject.

13. A luminescent in vivo glucose measurement method for measuring a glucose level in an interstitial fluid of a subject, comprising the steps of:

(a) providing an implanted luminescent in vivo measurement apparatus within said interstitial fluid, said implanted luminescent in vivo measurement apparatus comprising a container having an interior region, an illumination region wherein light may enter said interior region, an agglutinating layer on at least one surface of said interior region and apart from said illumination region, and luminescent molecules and associated captive glucose analogue molecules reversibly attached to said agglutinating layer;

(b) providing a means of allowing glucose from the subject to enter said interior region, said glucose causing said luminescent molecules and associated captive glucose analogue to become displaced from said agglutinating layer and into said illumination region;

(c) illuminating displaced luminescent molecules within said illumination region; and

(d) measuring an emitted light from said displaced luminescent molecules, said emitted light being emitted in response to said illumination;

wherein said emitted light is related to said glucose level in said interstitial fluid.

14. The luminescent in vivo glucose measurement method of claim 13, wherein said glucose level in said interstitial fluid is substantially equal to a blood glucose level.

15. The luminescent in vivo glucose measurement method of claim 13, wherein said method is used to measure a glucose level in a bloodstream of said subject.

16. The luminescent in vivo glucose measurement method of claim 13, wherein said displaced luminescent molecules are inorganic.

17. The luminescent in vivo glucose measurement method of claim 13, wherein said emitted light is correlated to a interstitial glucose level.

18. The luminescent in vivo glucose measurement method of claim 13, wherein said luminescent in vivo measurement apparatus is implanted about three to about four millimeters below an outer surface of a patient'"'"'s skin.

19. The luminescent in vivo glucose measurement method of claim 13, wherein said illuminating light is of a first wavelength and said emitted light is of a second wavelength.

20. The luminescent in vivo glucose measurement method of claim 13, wherein said illuminating light is an infrared light.

21. The luminescent in vivo glucose measurement method of claim 13, wherein a wavelength of said illuminating light is in a range of about 800 nanometers to about 2000 nanometers.

22. The luminescent in vivo glucose measurement method of claim 13, wherein a wavelength of said illuminating light is about 830 nanometers and a wavelength of said emitted light to about 900 nanometers.

23. The luminescent in vivo glucose measurement method of claim 13, wherein said illuminating light travels from outside said subject, through said subject'"'"'s skin, and into said luminescent in vivo measurement apparatus.

24. The luminescent in vivo glucose measurement method of claim 13, wherein said emitted light travels from said luminescent in vivo measurement apparatus, through said subject'"'"'s skin, and to a region outside said subject.